Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02334800 · ClinicalTrials.gov registry record · Phase 1
A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02334800 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 28 participants.
The verdict
NCT02334800, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a phase 1 study to describe the plasma pharmacokinetics of a single oral 75mg dose of palbociclib administered to healthy volunteers, and subjects with mild, moderate, and severely impaired hepatic function.
Interventions
- DRUG Palbociclib 75 mg Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2015-03-31 |
| Est. Completion | 2016-10-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02334800
The ClinicalTrials.gov registry entry for NCT02334800 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Palbociclib 75 mg Capsule is the first listed.
NCT02334800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02334800 about?
NCT02334800 is a clinical study titled "A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib". This is a phase 1 study to describe the plasma pharmacokinetics of a single oral 75mg dose of palbociclib administered to healthy volunteers, and subjects with mild, moderate, and severely impaired hepatic function.
What is the current status of trial NCT02334800?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2015-03-31. Estimated completion is 2016-10-09.
What interventions are being tested in trial NCT02334800?
The interventions under investigation include: Palbociclib 75 mg Capsule (DRUG).
Who is sponsoring clinical trial NCT02334800?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.